Antibody Contract Manufacturing Market Industry Trends and Global Forecast Report 2025-2035 | Monoclonal Antibodies Dominate Market, But Bispecific Antibodies Gain Traction [Yahoo! Finance...
Emergent Biosolutions, Inc. (EBS)
Last emergent biosolutions, inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: Yahoo! Finance
Monoclonal antibodies currently dominate, but bispecific antibodies are emerging. North America leads, with Asia showing high growth potential. Key market segments include monoclonal/bispecific antibodies, mammalian/microbial expression systems, and clinical/commercial scales. Antibody Contract Manufacturing Services Antibody Contract Manufacturing Services Benchmark Analysis Benchmark Analysis Atibody Contract Manufacturing Atibody Contract Manufacturing Dublin, Sept. 23, 2025 (GLOBE NEWSWIRE) -- The "Antibody Contract Manufacturing Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Antibody Manufactured, Type of Expression System Used, Scale of Operation and Geographical Regions" report has been added to ResearchAndMarkets.com's offering. The global antibody contract manufacturing market is estimated to grow from USD 16.6 billion in 2025, to USD 47 billion by 2035, at a CAGR of 10% during the forecast period, till 2035. Antibody Contract M
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent Biosolutions, Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EBS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
- Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone AccessGlobeNewswire
- Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors [Yahoo! Finance]Yahoo! Finance
EBS
Earnings
- 10/29/25 - Beat
EBS
Sec Filings
- 11/12/25 - Form 4
- 11/12/25 - Form 8-K
- 11/10/25 - Form 4
- EBS's page on the SEC website